PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811
Chinese Clinical Oncology · 2024
DOI: 10.21037/cco-24-28 ↗Kurz gefasst
Editorial in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von James Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adenocarcinoma, Stomach Neoplasms, Esophagogastric Junction.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Zitieren
APA
Yu, J., & Saeed, A. (2024). PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811. Chinese Clinical Oncology. https://doi.org/10.21037/cco-24-28
Vancouver
Yu J, Saeed A. PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811. Chinese Clinical Oncology. 2024. doi:10.21037/cco-24-28
BibTeX
@article{Yu2024,
author = {Yu, James and Saeed, Anwaar},
title = {PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811},
journal = {Chinese Clinical Oncology},
year = {2024},
doi = {10.21037/cco-24-28}
}
EUVIMED